Editorial
doi: 10.1016/j.jaci.2010.04.022.
IL-5 pathway inhibition in the treatment of asthma and Churg-Strauss syndrome
- PMID: 20513522
- DOI: 10.1016/j.jaci.2010.04.022
Item in Clipboard
Editorial
IL-5 pathway inhibition in the treatment of asthma and Churg-Strauss syndrome
J Allergy Clin Immunol.
2010 Jun.
No abstract available
Comment on
-
Treatment of patients with the hypereosinophilic syndrome with mepolizumab.N Engl J Med. 2008 Mar 20;358(12):1215-28. doi: 10.1056/NEJMoa070812. Epub 2008 Mar 16. N Engl J Med. 2008. PMID: 18344568 Clinical Trial.
-
Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma.J Allergy Clin Immunol. 2010 Jun;125(6):1237-1244.e2. doi: 10.1016/j.jaci.2010.04.005. J Allergy Clin Immunol. 2010. PMID: 20513521 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
